One of the many constantly recurring topics that we discuss is over the efficacy of intermittent hormone deprivation therapy (IAD) as opposed to continuous hormone deprivation therapy (CAD). Which therapy is better has been debated for at least ten years. The debate still rages over the question of efficacy, or survival as well as the [...]
The Debate Continues, Is IAD or CAD Superior for the Treatment of Men with Castrate Resistant Prostate Cancer?
A new randomized study (FinnProstate Study VII) on the merits of intermittent androgen deprivation (IAD) compared to continuous androgen therapy (CAD) contradicts the recent revelations from the last ASCO presentation (Hussain et.al) where the clear conclusion was that CAD was superior to IAD. At the ASCO conference Dr. Hussain’s study concluded that IAD was significantly [...]
Intermittent Androgen Deprivation (IAD)- No Longer Considered Experimental for Treating Men with Advanced Prostate Cancer
Changing the Standard of Care for Men with Recurrent and Advanced Prostate Cancer, Men receiving androgen deprivation therapy (ADT) for the treatment of advanced or metastatic prostate cancer know all to well the terrible side effects this treatment modality can cause. These side effects can include fatigue, hot flashes, mood swings, inability to concentrate as [...]
A recent Finnish study released interim results comparing intermittent androgen deprivation (IAD) to continuous androgen deprivation (CAD) in 856 men. All the men had locally advanced or metastatic prostate cancer and they all were treated at 27 clinics in Finland. The period of study was between 1997 and 2003 and all men were required to [...]